The A4 study was designed to evaluate safety, tolerability and efficacy of Solanezumab in older individuals who have normal thinking and memory function but who may be at risk for developing Alzheimer’s disease (AD) memory loss sometime in the future. The A4 study aims to evaluate the whether a new investigational treatment can slow the memory loss caused by Alzheimer’s disease. The overall goal of the A4 study is to test whether decreasing amyloid with antibody investigational treatment can help slow the memory loss associated with amyloid buildup in some people.

Visit the study website HERE

Closed to Enrollment

The purpose of this study is to examine the response to and clinical efficacy of a new drug called "BAN2401" from subjects with Early Alzheimer’s Disease. During this 18-month study, 3 different dose levels are given biweekly to separate groups of subjects and 2 dose levels are given monthly to separate groups of subjects. The 2 clinical subgroups are subjects with mild cognitive impairment (MCI) due to Alzheimer’s disease or mild Alzheimer’s Disease dementia. This is a placebo-controlled, double-blind, parallel-group study.

Visit the study website HERE

Closed to Enrollment

This longitudinal and cross-sectional study is designed to evaluate the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment (MCI), and subjects with Alzheimer’s Disease (AD). 18F-AV-1451 is a brain imaging agent used in PET (Positron Emission Tomography) Scans. Cognitively healthy participants receive an IV injection of Florbetapir, which is also a PET scanning compound used as a diagnostic tool for Alzheimer’s. Cross-sectional and longitudinal participants will receive a single dose injection of 18F-AV-1451. Only longitudinal participants will receive an IV injection of 18F-AV-1451 at 9 and 18 months. Exploratory MCI Subjects will receive an IV injection of Florbetapir at baseline, followed by an IV injection of 18F-AV-1451 at baseline, 9 months, and 18 months.

Visit the study website HERE

Closed to Enrollment

This purpose of this clinical trial is the test the idea that Solanezumab can be used as a neuroprotector to slow the cognitive and functional decline if Alzheimer’s Disease. Solanezumab is an antibody directed against the mid-domain of the harmful, AD-causing A-beta peptide. Participants with Mild Alzheimer’s Disease will being be given either Solanezumab every 4 weeks for 18 months, or a Placebo every 4 weeks for 18 months. The drugs are administered intravenously (IV). There is then an additional 4 weeks of assessment.

Visit the study website HERE

Closed to Enrollment

This clinical trial is examining the effects of an oral medication on those with mild to moderate AD currently on Aricept (Donepezil). The medication, "T-817MA" is designed to potentially treat Alzheimer’s disease by protecting brain cells. The drug is undergoing phase two trials in which it is being tested in patients with mild to moderate Alzheimer’s disease. Participants are given either T-817MA or placebo over a 14 month period. People participating in the trial will undergo various physical and cognitive tests with an MRI scan completed at the beginning and end of the study. Primary care doctors are kept informed about participant progress and lab results, and the participants receive regular health checks by professionals that specialize in Alzheimer’s disease.

Visit the study website HERE

Closed to Enrollment